Author

P. Lukacik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:protein structure· 1 Research Focus:protein structure prediction· 1 Assay:structural biology· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

C. Strain-Damerell· 2 shared D. FearoniD· 2 shared E. Resnick· 2 shared F. von DelftiD· 2 shared M. A. Walsh· 2 shared N. London· 2 shared P. Gehrtz· 2 shared A. aimon· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

C. Strain-Damerell

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

D. Zaidman, P. Gehrtz, M. Filep, D. Fearon, J. Prilusky, S. Duberstein, G. Cohen, D. Owen, E. Resnick, C. Strain-Damerell, P. Lukacik, Covid-Moonshot Consortium, H. Barr, M. A. Walsh, F. von Delft, N. London

The paper introduces a computational pipeline to design irreversible inhibitors, identifying a potent SARS-CoV-2 Mpro inhibitor with low micromolar IC50.

Cell Chemical Biology · Dec 1, 2021Peer-reviewedBiochemistry

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

A. Douangamath, D. Fearon, P. Gehrtz, T. Krojer, P. Lukacik, C. D. Owen, E. Resnick, C. Strain-Damerell, A. aimon, P. Abranyi-Balogh, J. Brandao-Neto, A. Carberry, G. Davison, A. Dias, T. D. Downes, , M. A. Walsh

The paper identifies fragment hits against SARS-CoV-2 main protease using crystallography and mass spectrometry, revealing structural insights for drug design.

bioRxiv · May 27, 2020Biophysics